R&G PharmaStudies Co. Ltd. A (301333) - Cash Flow Conversion Efficiency
Based on the latest financial reports, R&G PharmaStudies Co. Ltd. A (301333) has a cash flow conversion efficiency ratio of 0.090x as of June 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥40.98 Million ≈ $6.00 Million USD) by net assets (CN¥454.13 Million ≈ $66.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of R&G PharmaStudies Co. Ltd. A for the company's overall valuation and market capitalisation.
R&G PharmaStudies Co. Ltd. A - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how R&G PharmaStudies Co. Ltd. A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
R&G PharmaStudies Co. Ltd. A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of R&G PharmaStudies Co. Ltd. A ranked by their cash flow conversion efficiency. Explore R&G PharmaStudies Co. Ltd. A (301333) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Svenska Handelsbanken AB (publ)
ST:SHB-B
|
0.330x |
|
Jiangsu Asia Pacific Light Alloy Technology Co Ltd
SHE:002540
|
-0.018x |
|
Vontron Technology Co Ltd
SHE:000920
|
0.081x |
|
SAF Holland SA
XETRA:SFQ
|
0.082x |
|
Tips Music Limited
NSE:TIPSMUSIC
|
0.178x |
|
Chimera Investment Corporation
NYSE:CIM
|
-0.040x |
|
Power Generation Corp 3
VN:PGV
|
0.111x |
|
Wutong Holding Group Co Ltd
SHE:300292
|
-0.004x |
Annual Cash Flow Conversion Efficiency for R&G PharmaStudies Co. Ltd. A (2019–2025)
The table below shows the annual cash flow conversion efficiency of R&G PharmaStudies Co. Ltd. A from 2019 to 2025. View 301333 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.98 Billion ≈ $289.11 Million |
CN¥114.20 Million ≈ $16.71 Million |
0.058x | -31.42% |
| 2024-12-31 | CN¥1.84 Billion ≈ $268.68 Million |
CN¥154.76 Million ≈ $22.65 Million |
0.084x | -23.20% |
| 2023-12-31 | CN¥1.75 Billion ≈ $256.76 Million |
CN¥192.56 Million ≈ $28.18 Million |
0.110x | +34.06% |
| 2022-12-31 | CN¥1.59 Billion ≈ $233.21 Million |
CN¥130.47 Million ≈ $19.09 Million |
0.082x | -68.72% |
| 2021-12-31 | CN¥437.81 Million ≈ $64.07 Million |
CN¥114.57 Million ≈ $16.77 Million |
0.262x | +99.97% |
| 2020-12-31 | CN¥336.98 Million ≈ $49.31 Million |
CN¥44.10 Million ≈ $6.45 Million |
0.131x | -68.41% |
| 2019-12-31 | CN¥249.74 Million ≈ $36.55 Million |
CN¥103.48 Million ≈ $15.14 Million |
0.414x | -- |
About R&G PharmaStudies Co. Ltd. A
R&G PharmaStudies Co., Ltd. operates as a clinical trial outsourcing service provider in China and internationally. It offers drug clinical research and development integrated services. The company's services include clinical trial operation, clinical trial site management, biological sample testing, data management and statistical analysis, clinical trial consulting, and clinical pharmacology se… Read more